doi: 10.1016/j.ddstr.2011.02.004.
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer
Affiliations
- PMID: 21922023
- PMCID: PMC3172154
- DOI: 10.1016/j.ddstr.2011.02.004
Item in Clipboard
Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer
Drug Discov Today Ther Strateg.
.
Abstract
Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer. The use of novel agents targeting the androgen receptor and its signaling pathways offers a promising approach that is both safe and effective. We describe the rationale behind the use of these compounds in clinical development and the existing challenges as to how best to incorporate these new and emerging therapies in the changing treatment paradigm of metastatic prostate cancer.
Similar articles
-
Intermittent androgen deprivation therapy in advanced prostate cancer.Curr Treat Options Oncol. 2014 Mar;15(1):127-36. doi: 10.1007/s11864-013-0272-2. Curr Treat Options Oncol. 2014. PMID: 24395278 Review.
-
Targeting the androgen receptor signaling pathway in advanced prostate cancer.Am J Health Syst Pharm. 2022 Jul 22;79(15):1224-1235. doi: 10.1093/ajhp/zxac105. Am J Health Syst Pharm. 2022. PMID: 35390118 Review.
-
The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.Medicina (Kaunas). 2024 Oct 22;60(11):1727. doi: 10.3390/medicina60111727. Medicina (Kaunas). 2024. PMID: 39596912 Free PMC article. Review.
-
Contemporary role of androgen deprivation therapy for prostate cancer.Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Eur Urol. 2012. PMID: 21871711 Free PMC article. Review.
-
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.Cochrane Database Syst Rev. 2020 Dec 12;12(12):CD013245. doi: 10.1002/14651858.CD013245.pub2. Cochrane Database Syst Rev. 2020. PMID: 33314020 Free PMC article.
Cited by
-
Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.Receptors Clin Investig. 2014;1(5):10.14800%2Frci.122. doi: 10.14800/rci.122. Receptors Clin Investig. 2014. PMID: 25152898 Free PMC article.
-
Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer.Cancer Cell Int. 2025 Feb 3;25(1):33. doi: 10.1186/s12935-025-03658-5. Cancer Cell Int. 2025. PMID: 39901204 Free PMC article. Review.
-
Salinomycin Exerts Anticancer Effects on PC-3 Cells and PC-3-Derived Cancer Stem Cells In Vitro and In Vivo.Biomed Res Int. 2017;2017:4101653. doi: 10.1155/2017/4101653. Epub 2017 Jun 6. Biomed Res Int. 2017. PMID: 28676857 Free PMC article.
-
Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res. 2022 Apr 14;28(8):1549-1559. doi: 10.1158/1078-0432.CCR-21-4049. Clin Cancer Res. 2022. PMID: 35110415 Free PMC article. Clinical Trial.
-
Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.Prostate Cancer Prostatic Dis. 2018 Apr;21(1):137-146. doi: 10.1038/s41391-017-0016-7. Epub 2018 Jan 16. Prostate Cancer Prostatic Dis. 2018. PMID: 29339807 Free PMC article.
References
-
- Jemal A, et al. Cancer Statistics. CA Cancer J Clin. 2010 2010. Epub ahead of print. - PubMed
-
- Pound CR, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–1597. - PubMed
-
- Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 1952;12(2):134–141. - PubMed
-
- Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351(15):1488–1490. - PubMed
-
- Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources